SGMT — Sagimet Biosciences Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1400118 ·
Last close
$7.22
Market Cap
$441.75M
52W High
$9.37
52W Low
$4.50
ADV30
2,580,474
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,713,000 | -10,650,000 | 107,755,000 | 36,626,000 | 5,297,000 |
| Dec 2025 | 0 | — | -10,765,000 | -9,568,000 | 116,482,000 | 35,021,000 | 5,101,000 |
| Sep 2025 | 0 | — | -14,334,000 | -12,908,000 | 128,401,000 | 32,496,000 | 9,146,000 |
| Jun 2025 | 0 | — | -11,925,000 | -10,386,000 | 137,407,000 | 42,327,000 | 7,247,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-45,650,000
Investing CF
$4,556,000
Financing CF
$275,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.57
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-346,349,000
Inventory
—
Receivables
—
ST Investments
$78,103,000
EBIT TTM
$-56,889,000
Pretax Income TTM
$-51,038,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -56,889,000 | -51,038,000 | 116,482,000 | 5,101,000 | — | -45,650,000 |
| Dec 2024 | 0 | -54,454,000 | -45,567,000 | 160,259,000 | 4,454,000 | — | -42,435,000 |
| Dec 2023 | 2,000,000 | -30,740,000 | -27,876,000 | 96,719,000 | 5,654,000 | — | -23,766,000 |
| Dec 2022 | 0 | -31,055,000 | -30,499,000 | 33,031,000 | 219,981,000 | — | -24,490,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.31
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADCT | ADC Therapeutics SA | $446.44M | $3.51 | — |
| UPB | Upstream Bio, Inc. | $446.79M | $8.21 | — |
| CTNM | Contineum Therapeutics, Inc. | $448.32M | $13.70 | — |
| FBRX | Forte Biosciences, Inc. | $449.31M | $21.94 | — |
| FULC | Fulcrum Therapeutics, Inc. | $450.44M | $6.76 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
2026-05-21 13:55 · Yahoo
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
2026-05-13 11:00 · Yahoo
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-12 11:30 · Yahoo
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
2026-05-11 11:00 · Yahoo
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
2026-05-05 16:00 · Yahoo
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
2026-05-05 13:55 · Yahoo
Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise
2026-05-01 04:07 · Yahoo
Why Sagimet Biosciences Stock Is Soaring Today
2026-04-27 16:00 · Yahoo
Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans
2026-04-27 15:13 · Yahoo
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
2026-04-27 11:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.